Cargando…

How far are we from a medication use process aiming at well-informed adherent patients with long-term medications in Finland? Qualitative study

OBJECTIVE: Finland is one of the few countries that has established a national Medicines Information (MI) Strategy. The ultimate goal of the strategy is a well-implemented medication use process resulting in well-informed adherent patients. This study aimed at evaluating the implementation of the st...

Descripción completa

Detalles Bibliográficos
Autores principales: Mononen, Niina, Pohjanoksa-Mäntylä, Marika, Airaksinen, Marja SA, Hämeen-Anttila, Katri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307543/
https://www.ncbi.nlm.nih.gov/pubmed/32565471
http://dx.doi.org/10.1136/bmjopen-2019-036526
_version_ 1783548829143924736
author Mononen, Niina
Pohjanoksa-Mäntylä, Marika
Airaksinen, Marja SA
Hämeen-Anttila, Katri
author_facet Mononen, Niina
Pohjanoksa-Mäntylä, Marika
Airaksinen, Marja SA
Hämeen-Anttila, Katri
author_sort Mononen, Niina
collection PubMed
description OBJECTIVE: Finland is one of the few countries that has established a national Medicines Information (MI) Strategy. The ultimate goal of the strategy is a well-implemented medication use process resulting in well-informed adherent patients. This study aimed at evaluating the implementation of the strategy 3 years after its launch. DESIGN: The evaluation applied a pragmatic approach and was conducted by interviewing stakeholders involved in the National MI Network enhancing the MI Strategy’s implementation. The network comprises national key stakeholders producing and using MI. Data were deductively analysed according to the medication use process of the MI Strategy using the framework method, complemented with inductively derived categories. SETTING: National implementation of the MI Strategy throughout the healthcare system after the first operational period (2012–2014) in 2015. PARTICIPANTS: The members of the National MI Network (n=79/111, participation rate 71%, representing 42/53 stakeholder organisations). OUTCOME MEASURES: A new conceptual framework was developed based on stakeholders’ views on well-implemented actions and actions needing development in the medication use process at (1) infrastructure (macro), (2) healthcare professionals (meso) and (3) patient (micro) levels. RESULTS: Medication counselling by community pharmacists was the primary implemented action, followed by physicians’ actions while starting a new medication, and advice given by nurses. The major development needs concerned (1) poor access to patient information and its transfer in healthcare, particularly the lack of reconciled medication lists and electronic health records (macro); (2) poorly functioning medication use process in home care and social care units, such as nursing homes (meso); and (3) limited patient involvement in their care (micro). CONCLUSIONS: Far more actions for development than well-established practices in the medication use process were identified. Major challenges found in this evaluation are considered in the ongoing Rational Pharmacotherapy Action Plan 2018–2022 by the Ministry of Social Affairs and Health.
format Online
Article
Text
id pubmed-7307543
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-73075432020-06-23 How far are we from a medication use process aiming at well-informed adherent patients with long-term medications in Finland? Qualitative study Mononen, Niina Pohjanoksa-Mäntylä, Marika Airaksinen, Marja SA Hämeen-Anttila, Katri BMJ Open Health Policy OBJECTIVE: Finland is one of the few countries that has established a national Medicines Information (MI) Strategy. The ultimate goal of the strategy is a well-implemented medication use process resulting in well-informed adherent patients. This study aimed at evaluating the implementation of the strategy 3 years after its launch. DESIGN: The evaluation applied a pragmatic approach and was conducted by interviewing stakeholders involved in the National MI Network enhancing the MI Strategy’s implementation. The network comprises national key stakeholders producing and using MI. Data were deductively analysed according to the medication use process of the MI Strategy using the framework method, complemented with inductively derived categories. SETTING: National implementation of the MI Strategy throughout the healthcare system after the first operational period (2012–2014) in 2015. PARTICIPANTS: The members of the National MI Network (n=79/111, participation rate 71%, representing 42/53 stakeholder organisations). OUTCOME MEASURES: A new conceptual framework was developed based on stakeholders’ views on well-implemented actions and actions needing development in the medication use process at (1) infrastructure (macro), (2) healthcare professionals (meso) and (3) patient (micro) levels. RESULTS: Medication counselling by community pharmacists was the primary implemented action, followed by physicians’ actions while starting a new medication, and advice given by nurses. The major development needs concerned (1) poor access to patient information and its transfer in healthcare, particularly the lack of reconciled medication lists and electronic health records (macro); (2) poorly functioning medication use process in home care and social care units, such as nursing homes (meso); and (3) limited patient involvement in their care (micro). CONCLUSIONS: Far more actions for development than well-established practices in the medication use process were identified. Major challenges found in this evaluation are considered in the ongoing Rational Pharmacotherapy Action Plan 2018–2022 by the Ministry of Social Affairs and Health. BMJ Publishing Group 2020-06-21 /pmc/articles/PMC7307543/ /pubmed/32565471 http://dx.doi.org/10.1136/bmjopen-2019-036526 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Health Policy
Mononen, Niina
Pohjanoksa-Mäntylä, Marika
Airaksinen, Marja SA
Hämeen-Anttila, Katri
How far are we from a medication use process aiming at well-informed adherent patients with long-term medications in Finland? Qualitative study
title How far are we from a medication use process aiming at well-informed adherent patients with long-term medications in Finland? Qualitative study
title_full How far are we from a medication use process aiming at well-informed adherent patients with long-term medications in Finland? Qualitative study
title_fullStr How far are we from a medication use process aiming at well-informed adherent patients with long-term medications in Finland? Qualitative study
title_full_unstemmed How far are we from a medication use process aiming at well-informed adherent patients with long-term medications in Finland? Qualitative study
title_short How far are we from a medication use process aiming at well-informed adherent patients with long-term medications in Finland? Qualitative study
title_sort how far are we from a medication use process aiming at well-informed adherent patients with long-term medications in finland? qualitative study
topic Health Policy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307543/
https://www.ncbi.nlm.nih.gov/pubmed/32565471
http://dx.doi.org/10.1136/bmjopen-2019-036526
work_keys_str_mv AT mononenniina howfararewefromamedicationuseprocessaimingatwellinformedadherentpatientswithlongtermmedicationsinfinlandqualitativestudy
AT pohjanoksamantylamarika howfararewefromamedicationuseprocessaimingatwellinformedadherentpatientswithlongtermmedicationsinfinlandqualitativestudy
AT airaksinenmarjasa howfararewefromamedicationuseprocessaimingatwellinformedadherentpatientswithlongtermmedicationsinfinlandqualitativestudy
AT hameenanttilakatri howfararewefromamedicationuseprocessaimingatwellinformedadherentpatientswithlongtermmedicationsinfinlandqualitativestudy